Context Therapeutics' CTIM-76 Achieves 29% ORR in Heavily Pre-Treated Ovarian Cancer Patients
CNTX has more than doubled off its 52-week low of $0.56.
Summary
Context Therapeutics announced positive interim Phase 1 results for its lead candidate, CTIM-76, in platinum-resistant ovarian cancer (PROC). The drug achieved a 29% overall response rate (ORR) in heavily pre-treated patients who had failed a median of seven prior therapies, alongside a favorable safety profile with cytokine release syndrome (CRS) limited to Grade 1 in 11% of patients. This positive clinical update follows the FDA Fast Track Designation for CTIM-76 in April and prior reports of partial responses in March. The company has faced recent financial challenges, including increased cash burn and a proposed significant share increase, making this clinical progress critical. Context plans to explore a Q3W dosing schedule in the second half of 2026, with Phase 1b dose expansion expected in 2027.
At the time of this announcement, CNTX was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.7M. The 52-week trading range was $0.56 to $3.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.